Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) will be discussing 2Q20 financial results with the investment community.on 11th August 2020 at 4:30 PM eastern time.
Those interested in listening to the conference call live via the Internet can visit www.sunesis.com
Earnings Expectation
Sunesis Pharmaceuticals, Inc. is reporting second quarter financial results on Tuesday 11th August 2020, after market close.
According to analysts surveyed by Thomson Reuters, SNSS is expected to report 2Q20 loss of $ 0.06 per share from revenue of $ 0.19 million. For the full year, analysts anticipate top line of $ 0.54 million, while looking forward to loss of $ 0.2 per share bottom line.
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalent inhibitor of Brutons tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, a topoisomerase 2 inhibitor, which completed a Phase 3 trial in patients with relapsed or refractory acute myeloid leukemia.
